Evonik Evonik

X
[{"orgOrder":0,"company":"Etana Biotechnologies","sponsor":"Yunfeng Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Etana Has Secured Financing From Deg, East Ventures And Other Global Investors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Etana Biotechnologies

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The financing will be used for further strengthening the company’s pipeline and portfolio especially in Oncology area. Etana will produce Bevagen (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug for cancer patients in Indonesia.

            Lead Product(s): Bevacizumab

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Yunfeng Capital

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing March 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY